12:00 AM
 | 
Apr 03, 2000
 |  BC Week In Review  |  Company News  |  Deals

PharmaNetics, Schering deal

The companies signed a materials transfer agreement under which PHAR will evaluate Schering's Solulin genetically engineered thrombomodulin to improve...

Read the full 93 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >